查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1662875

抗瘧疾藥市場預測至 2030 年：按藥物類型、藥物類別、瘧疾類型、給藥方式、分銷管道、最終用戶和地區進行的全球分析

Anti-Malarial Drugs Market Forecasts to 2030 - Global Analysis By Drug Type, Drug Class, Malaria Type, Mode of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球抗瘧疾藥市場預計在 2024 年達到 10.441 億美元，到 2030 年預計將達到 14.396 億美元，預測期內的複合年成長率為 5.5%。

抗瘧疾藥是用於預防或治療瘧疾原蟲引起的寄生蟲感染疾病的藥物。這些藥物針對的是人體內處於生命週期不同階段的寄生蟲。常見的抗瘧疾藥包括Chloroquine、奎寧和青蒿素為基礎的聯合治療（ACT）。它們透過抑制紅血球內寄生蟲的生長、複製和存活發揮作用。抗瘧疾藥在瘧疾流行地區至關重要，瘧疾是主要的公共衛生威脅。它也用於防止旅行者前往高風險地區。

根據2021年12月發布的最新《世界瘧疾報告》，2020年全球估計有2.41億例瘧疾病例，導致6.27億人死亡。這意味著與 2019 年相比，2020 年的病例增加了約 1,400 萬例，死亡人數增加了 69,000 人。

醫療支出增加

瘧疾發病率上升和有效治療需求增加推動了市場醫療保健支出的增加。各國政府和組織正在撥出更多資金用於瘧疾控制，並致力於改善瘧疾流行地區獲得這些藥物的機會。不斷加強的研究和開發以及對創新解決方案的需求有助於開發市場，確保全球範圍內更好的醫療保健基礎設施和更有效的治療。

可用性和可負擔性

抗瘧疾藥的供應和負擔能力可能會對市場產生嚴重的負面影響。在經濟困難地區，高昂的藥物成本和不足的衛生基礎設施阻礙了及時治療，導致瘧疾相關死亡率上升。此外，無法持續獲得藥物會導致抗藥性，使治療結果變得複雜。這些差異加劇了公共衛生危機，特別是在低收入和偏遠地區，阻礙了控制瘧疾的進展，並阻礙了整體市場的成長。

瘧疾盛行率高

瘧疾的高發性對市場產生了重大影響，推動了對有效治療的需求。治療總是需要的，特別是在瘧疾負擔較重的地區，例如撒哈拉以南非洲和東南亞。患者數量的不斷成長促使政府和衛生組織對藥品供應、研究和分銷進行投資。這種需求，加上對現有治療方法的抵制日益增加，進一步推動了市場成長。

認知和教育有限

對於瘧疾及其治療的認知和教育有限可能會對市場產生負面影響。缺乏知識可能導致不當使用藥物，從而產生抗藥性和降低療效。對預防方法缺乏了解可能會導致治療延誤和傳播率增加。缺乏教育阻礙了對所需藥物的需求，減緩了瘧疾控制工作，並抑制了市場成長，尤其是在農村和偏遠地區。

COVID-19 的影響

新冠肺炎疫情分散了人們對瘧疾控制的資源和注意力，擾亂了市場。供應鏈中斷、衛生系統緊張以及瘧疾流行地區藥品取得有限，導致治療延誤。此外，這次疫情也引發了人們對某些抗瘧疾藥對抗新冠肺炎有效性的爭論和困惑，影響了瘧疾患者對這些藥物的可近性。這對瘧疾治療整體和市場穩定產生了負面影響。

預計奎寧部分將在預測期內佔據最大的市場佔有率

預計預測期內奎寧將佔據最大的市場佔有率。奎寧仍然是市面上重要的抗瘧疾藥，尤其是在治療嚴重瘧疾的情況下。奎寧取自金雞納樹皮，已被使用了幾個世紀。儘管出現了新藥，奎寧仍然被廣泛使用，特別是在抗藥性普遍存在的地區。由於其經濟實惠和有效性，它成為一種必不可少的治療方法，尤其是在一線治療失敗或在無法獲得先進療法的地區。

預計預測期內醫院部門將以最高的複合年成長率成長。

預計預測期內醫院部門將呈現最高的成長率。該醫院是抗瘧疾藥的重要分銷點，提供住院和門診治療。醫院透過提供正確的診斷和管理有效的藥物治療方案（包括奎寧和較新的治療方法）為市場成長做出了貢獻。他們在瘧疾流行地區發揮至關重要的作用，幫助控制疫情、教育患者並改善整體治療機會。

比最大的地區

在預測期內，由於瘧疾盛行率較低，預計北美將佔據最大的市場佔有率。但對於旅行者、軍事相關人員和管理輸入病例的衛生專業人員來說，它仍然很重要。北美製藥公司生產抗瘧疾藥，服務全球市場，並專注於抗藥性和創新治療方法的研究。各國政府也支持瘧疾流行國家的消除瘧疾舉措，間接影響當地的市場動態。

複合年成長率最高的地區

預計預測期內亞太地區將呈現最高的複合年成長率。印度、中國和印尼等國家每年報告大量瘧疾病例，需要有效的抗瘧治療。不斷努力開發新的藥物組合和配方正在促進市場的擴大。此外，這些國家人口眾多，瘧疾發生率高，是市場的主要貢獻者。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 主要企業的 SWOT 分析（最多 3 家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭性基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二手研究資料資訊來源
    • 先決條件

第3章 市場走勢分析

  • 介紹
  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球抗瘧疾藥市場按藥物類型分類

  • 介紹
  • Chloroquine
  • 奎寧
  • 青蒿素聯合治療（ACT）
  • 甲氟喹
  • 伯氨喹
  • 其他藥物類型

6. 全球抗瘧疾藥市場依藥物類別分類

  • 介紹
  • 青蒿素
  • 抗葉酸
  • 金雞納生物鹼
  • 阿托伐醌-氯胍

7. 全球抗瘧疾藥市場依瘧疾類型分類

  • 介紹
  • 瘧疾原蟲瘧原蟲
  • 瘧疾原蟲
  • 瘧疾原蟲
  • 瘧疾原蟲瘧原蟲

8. 全球抗瘧疾藥市場依給藥方式分類

  • 介紹
  • 口服
  • 注射/靜脈注射
  • 局部的

9. 全球抗瘧疾藥市場依通路分類

  • 介紹
  • 政府和非政府組織項目
  • 零售藥局
  • 網路藥局

第 10 章 全球抗瘧疾藥市場（依最終用戶分類）

  • 介紹
  • 醫院
  • 診所和健康中心
  • 居家醫療
  • 其他

第 11 章 全球抗瘧疾藥市場（按地區）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司概況

  • Novartis
  • Sanofi
  • GlaxoSmithKline
  • Bayer
  • Cipla
  • Mylan
  • Merck & Co.
  • Lupin Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Sumitomo Dainippon Pharma
  • Aurobindo Pharma
  • Dr. Reddy's Laboratories
  • Hetero Healthcare
  • Bharat BIoTech
  • Takeda Pharmaceutical Company
  • Bausch Health
Product Code: SMRC28737

According to Stratistics MRC, the Global Anti-Malarial Drugs Market is accounted for $1044.1 million in 2024 and is expected to reach $1439.6 million by 2030 growing at a CAGR of 5.5% during the forecast period. Anti-Malarial Drugs are medications used to prevent or treat malaria, a parasitic infection caused by Plasmodium species. These drugs target the parasite at various stages of its lifecycle in the human body. Common anti-malarials include chloroquine, quinine, and artemisinin-based combination therapies (ACTs). They work by inhibiting parasite growth, replication, or survival within red blood cells. Anti-Malarial Drugs are crucial in malaria-endemic regions, where the disease poses a significant public health threat. They are also used for prophylaxis in travelers visiting high-risk areas.

According to the latest World Malaria Report, released in December 2021, there were an estimated 241 million cases of malaria and 627,000 resulting deaths worldwide in 2020. This represents about 14 million more cases in 2020 compared to 2019, and 69,000 more deaths.

Market Dynamics:

Driver:

Increasing healthcare expenditure

The increasing healthcare expenditure in the market is driven by rising malaria incidences and the growing demand for effective treatments. Governments and organizations are allocating more funds to combat malaria, focusing on improving access to these drugs in endemic regions. Enhanced research and development efforts, along with the need for innovative solutions, contribute to expanding the market, ensuring better healthcare infrastructure and more effective treatments worldwide.

Restraint:

Accessibility and affordability

Limited accessibility and affordability of Anti-Malarial Drugs can have severe negative effects on the market. In regions with economic challenges, high drug costs and inadequate healthcare infrastructure hinder timely treatment, leading to increased malaria-related mortality. Inconsistent access also fosters drug resistance, complicating treatment effectiveness. This disparity exacerbates public health crises, particularly in low-income and remote areas, preventing progress in controlling malaria and impeding overall market growth.

Opportunity:

High prevalence of malaria

The high prevalence of malaria significantly impacts the market, driving demand for effective treatments. Regions with a high burden of malaria, especially in sub-Saharan Africa and Southeast Asia, experience constant need for these drugs. The increasing number of cases prompts governments and health organizations to invest in drug accessibility, research, and distribution. This demand, coupled with rising resistance to existing treatments, further fuels market growth.

Threat:

Limited awareness and education

Limited awareness and education about malaria and its treatment can negatively impact the market. Lack of knowledge leads to improper use of drugs, contributing to resistance and reduced effectiveness. Inadequate understanding of prevention methods results in delayed treatment and higher transmission rates. This lack of education, especially in rural or remote areas, hinders demand for necessary drugs, slowing efforts to control malaria and impeding market growth.

Covid-19 Impact:

The COVID-19 pandemic disrupted the market by diverting resources and attention away from malaria control efforts. Supply chain interruptions, healthcare system strain, and limited access to drugs in malaria-endemic regions resulted in delays in treatment. Additionally, the pandemic sparked debates over the efficacy of certain Anti-Malarial Drugs for COVID-19, creating confusion and affecting their availability for malaria patients. This negatively impacted overall malaria treatment and market stability.

The quinine segment is expected to be the largest market share during the forecast period

The quinine segment is expected to account for the largest market share during the forecast period. Quinine remains a crucial anti-malarial drug in the market, particularly in severe cases of malaria. It is derived from the bark of the cinchona tree and has been used for centuries. Despite the emergence of newer drugs, quinine is still widely prescribed, especially in regions with drug resistance. Its affordability and effectiveness make it an essential treatment, especially when first-line therapies fail or in areas with limited access to advanced medications.

The hospitals segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals segment is predicted to witness the highest growth rate. They are key distribution points for anti-malarial medications, offering both inpatient and outpatient care. Hospitals contribute to market growth by ensuring proper diagnosis and administering effective drug regimens, including quinine and newer therapies. Their role is critical in malaria-endemic regions, where they help manage outbreaks, educate patients, and improve overall treatment access.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to the region's low malaria prevalence. However, it remains significant for travelers, military personnel, and healthcare professionals managing imported cases. North American pharmaceutical companies contribute to the global market by producing Anti-Malarial Drugs, and research focuses on drug resistance and innovative treatments. Governments also support malaria eradication initiatives in endemic countries, indirectly affecting the regional market dynamics.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Countries such as India, China, and Indonesia report a substantial number of malaria cases annually, necessitating effective anti-malarial treatments. Ongoing initiatives to develop new drug combinations and formulations are contributing to market expansion. Additionally, These countries are major contributors to the market due to their large populations and high malaria incidence rates.

Key players in the market

Some of the key players in Anti-Malarial Drugs market include Novartis, Sanofi, GlaxoSmithKline, Bayer, Cipla, Mylan, Merck & Co., Lupin Pharmaceuticals, Teva Pharmaceutical Industries, Sumitomo Dainippon Pharma, Aurobindo Pharma, Dr. Reddy's Laboratories, Hetero Healthcare, Bharat Biotech, Takeda Pharmaceutical Company and Bausch Health.

Key Developments:

In December 2024, Aurobindo Pharma Ltd said its step-down subsidiary CuraTeQ Biologics s.r.o. has received marketing authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, its biosimilar version of bevacizumab..

In April 2024, Novartis and Medicines for Malaria Venture (MMV) announced positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem(R) (artemether-lumefantrine) developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and good efficacy and safety.

Drug Types Covered:

  • Chloroquine
  • Quinine
  • Artemisinin-Based Combination Therapies (ACTs)
  • Mefloquine
  • Primaquine
  • Other Drug Types

Drug Classes Covered:

  • Artemisinin
  • Antifolate Drugs
  • Cinchona Alkaloids
  • Atovaquone-Proguanil

Malaria Types Covered:

  • Plasmodium Falciparum
  • Plasmodium Vivax
  • Plasmodium Malaria
  • Plasmodium Ovale

Mode of Administrations Covered:

  • Oral
  • Injectable/Intravenous
  • Topical

Distribution Channels Covered:

  • Government & NGO Programs
  • Retail Pharmacies
  • Online Pharmacies

End Users Covered:

  • Hospitals
  • Clinics and Health Centers
  • Home Care Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Anti-malarial Drugs Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Chloroquine
  • 5.3 Quinine
  • 5.4 Artemisinin-Based Combination Therapies (ACTs)
  • 5.5 Mefloquine
  • 5.6 Primaquine
  • 5.7 Other Drug Types

6 Global Anti-malarial Drugs Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Artemisinin
  • 6.3 Antifolate Drugs
  • 6.4 Cinchona Alkaloids
  • 6.5 Atovaquone-Proguanil

7 Global Anti-malarial Drugs Market, By Malaria Type

  • 7.1 Introduction
  • 7.2 Plasmodium Falciparum
  • 7.3 Plasmodium Vivax
  • 7.4 Plasmodium Malaria
  • 7.5 Plasmodium Ovale

8 Global Anti-malarial Drugs Market, By Mode of Administration

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Injectable/Intravenous
  • 8.4 Topical

9 Global Anti-malarial Drugs Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Government & NGO Programs
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies

10 Global Anti-malarial Drugs Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Clinics and Health Centers
  • 10.4 Home Care Settings
  • 10.5 Other End Users

11 Global Anti-malarial Drugs Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Novartis
  • 13.2 Sanofi
  • 13.3 GlaxoSmithKline
  • 13.4 Bayer
  • 13.5 Cipla
  • 13.6 Mylan
  • 13.7 Merck & Co.
  • 13.8 Lupin Pharmaceuticals
  • 13.9 Teva Pharmaceutical Industries
  • 13.10 Sumitomo Dainippon Pharma
  • 13.13 Aurobindo Pharma
  • 13.12 Dr. Reddy's Laboratories
  • 13.13 Hetero Healthcare
  • 13.14 Bharat Biotech
  • 13.15 Takeda Pharmaceutical Company
  • 13.16 Bausch Health

List of Tables

  • Table 1 Global Anti-malarial Drugs Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Anti-malarial Drugs Market Outlook, By Drug Type (2022-2030) ($MN)
  • Table 3 Global Anti-malarial Drugs Market Outlook, By Chloroquine (2022-2030) ($MN)
  • Table 4 Global Anti-malarial Drugs Market Outlook, By Quinine (2022-2030) ($MN)
  • Table 5 Global Anti-malarial Drugs Market Outlook, By Artemisinin-Based Combination Therapies (ACTs) (2022-2030) ($MN)
  • Table 6 Global Anti-malarial Drugs Market Outlook, By Mefloquine (2022-2030) ($MN)
  • Table 7 Global Anti-malarial Drugs Market Outlook, By Primaquine (2022-2030) ($MN)
  • Table 8 Global Anti-malarial Drugs Market Outlook, By Other Drug Types (2022-2030) ($MN)
  • Table 9 Global Anti-malarial Drugs Market Outlook, By Drug Class (2022-2030) ($MN)
  • Table 10 Global Anti-malarial Drugs Market Outlook, By Artemisinin (2022-2030) ($MN)
  • Table 11 Global Anti-malarial Drugs Market Outlook, By Antifolate Drugs (2022-2030) ($MN)
  • Table 12 Global Anti-malarial Drugs Market Outlook, By Cinchona Alkaloids (2022-2030) ($MN)
  • Table 13 Global Anti-malarial Drugs Market Outlook, By Atovaquone-Proguanil (2022-2030) ($MN)
  • Table 14 Global Anti-malarial Drugs Market Outlook, By Malaria Type (2022-2030) ($MN)
  • Table 15 Global Anti-malarial Drugs Market Outlook, By Plasmodium Falciparum (2022-2030) ($MN)
  • Table 16 Global Anti-malarial Drugs Market Outlook, By Plasmodium Vivax (2022-2030) ($MN)
  • Table 17 Global Anti-malarial Drugs Market Outlook, By Plasmodium Malaria (2022-2030) ($MN)
  • Table 18 Global Anti-malarial Drugs Market Outlook, By Plasmodium Ovale (2022-2030) ($MN)
  • Table 19 Global Anti-malarial Drugs Market Outlook, By Mode of Administration (2022-2030) ($MN)
  • Table 20 Global Anti-malarial Drugs Market Outlook, By Oral (2022-2030) ($MN)
  • Table 21 Global Anti-malarial Drugs Market Outlook, By Injectable/Intravenous (2022-2030) ($MN)
  • Table 22 Global Anti-malarial Drugs Market Outlook, By Topical (2022-2030) ($MN)
  • Table 23 Global Anti-malarial Drugs Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 24 Global Anti-malarial Drugs Market Outlook, By Government & NGO Programs (2022-2030) ($MN)
  • Table 25 Global Anti-malarial Drugs Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 26 Global Anti-malarial Drugs Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 27 Global Anti-malarial Drugs Market Outlook, By End User (2022-2030) ($MN)
  • Table 28 Global Anti-malarial Drugs Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 29 Global Anti-malarial Drugs Market Outlook, By Clinics and Health Centers (2022-2030) ($MN)
  • Table 30 Global Anti-malarial Drugs Market Outlook, By Home Care Settings (2022-2030) ($MN)
  • Table 31 Global Anti-malarial Drugs Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.